Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir

被引:135
|
作者
Nolan, D
Upton, R
McKinnon, E
John, M
James, I
Adler, B
Roff, C
Vasikaran, S
Mallal, S [1 ]
机构
[1] Royal Perth Hosp, Dept Clin Immunol, Ctr Clin Immunol & Biomed Stat, Perth, WA 6000, Australia
[2] Murdoch Univ, Murdoch, WA 6150, Australia
[3] Royal Perth Hosp, Dept Nucl Med, Perth, WA, Australia
[4] Royal Perth Hosp, Dept Core Clin Pathol & Biochem, Perth, WA, Australia
关键词
bone mineral density; HAART; indinavir; lipodystrophy syndrome; nelfinavir; protease inhibitors; osteopenia; osteoporosis; subcutaneous fat wasting;
D O I
10.1097/00002030-200107060-00009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background and objectives: To determine the factors contributing to changes in bone mineral density (BMD) over time in HIV-infected patients receiving highly active antiretroviral therapy (HAART). Methods: Analyses of lumbar spine BMD in 183 male Caucasian participants in the Western Australian HIV Cohort study, comprising a longitudinal analysis of data from 54 patients on stable HAART regimens, and a cross-sectional analysis comparing data from 131 protease inhibitor (PI)-treated patients and 52 PI-naive (including 28 antiretroviral treatment-naive) patients. Results: Average lumbar spine BMD remained stable or increased over the time frame considered. Although there was no evidence of a change of average BMD over time in patients receiving nelfinavir (P = 0.92), there was evidence of increasing bone density in the indinavir group (average increase, 0.31 z-score per year; P < 0.001). Lower initial z-scores in the longitudinal analysis were significantly associated with lower pre-HAART BMI (P = 0.003), consistent with results of the cross-sectional analysis in which lowest BMI prior to initial dual X-ray absorptiometry scan was associated with decreased BMD (P = 0.02, overall group). Although PI therapy was also associated with decreased BMD in a univariate analysis of the cross-sectional data (P = 0.04), this effect was abrogated in a multiple linear regression analysis (P = 0.11) with lowest BMI remaining significant (P = 0.04). Conclusions: We found no evidence, overall, of accelerated bone loss in patients treated with nelfinavir- or indinavir-containing HAART regimens, and propose that indinavir therapy may be associated with an increase in bone mineral density over time. Pre-HAART BMI was an independent and powerful determinant of an individual's initial z-score in the longitudinal analysis, and adjustment for this effect in a cross-sectional analysis abrogated the association between P1 therapy and decreased lumbar spine z-score. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:1275 / 1280
页数:6
相关论文
共 50 条
  • [21] Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy
    Mark J. Bolland
    Anne M. Horne
    Simon E. Briggs
    Mark G. Thomas
    Ian R. Reid
    Greg D. Gamble
    Andrew Grey
    Calcified Tissue International, 2019, 105 : 423 - 429
  • [22] Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy
    Bolland, Mark J.
    Horne, Anne M.
    Briggs, Simon E.
    Thomas, Mark G.
    Reid, Ian R.
    Gamble, Greg D.
    Grey, Andrew
    CALCIFIED TISSUE INTERNATIONAL, 2019, 105 (04) : 423 - 429
  • [23] Therapeutic Options for Low Bone Mineral Density in HIV-Infected Subjects
    Cotter, Aoife G.
    Mallon, Patrick W. G.
    CURRENT HIV/AIDS REPORTS, 2012, 9 (02) : 148 - 159
  • [24] TOOLS TO IDENTIFY LOW BONE MINERAL DENSITY IN HIV-INFECTED MEN
    Vieira, R.
    Oliveira, J.
    Lau, E.
    Serrao, R.
    Sarmento, A.
    Pereira, J.
    Costa, L.
    Carvalho, D.
    Freitas, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 766 - 766
  • [25] Screening for Osteoporosis and Low Bone Mineral Density in HIV-Infected Men
    Albright, Patsi
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 : S424 - S425
  • [26] Low Bone Mineral Density in Vertically HIV-infected Children and Adolescents
    Jimenez, Beatriz
    Sainz, Talia
    Diaz, Laura
    Jose Mellado, Maria
    Luisa Navarro, Maria
    Rojo, Pablo
    Isabel Gonzalez-Tome, Maria
    Prieto, Luis
    Martinez, Jorge
    Isabel de Jose, Maria
    Tomas Ramos, Jose
    Angeles Munoz-Fernandez, Maria
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2017, 36 (06) : 578 - 583
  • [27] Therapeutic Options for Low Bone Mineral Density in HIV-Infected Subjects
    Aoife G. Cotter
    Patrick W. G. Mallon
    Current HIV/AIDS Reports, 2012, 9 : 148 - 159
  • [28] Effect of Testosterone Use on Bone Mineral Density in HIV-Infected Men
    Grant, Philip M.
    Li, Xiuhong
    Jacobson, Lisa P.
    Palella, Frank J., Jr.
    Kingsley, Lawrence A.
    Margolick, Joseph B.
    Dobs, Adrian S.
    Lake, Jordan E.
    Althoff, Keri N.
    Brown, Todd T.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2019, 35 (01) : 75 - 80
  • [29] Effect of indinavir on the pharmacokinetics of rifampicin in HIV-infected patients
    Jaruratanasirikul, S
    Sriwiriyajan, S
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2001, 53 (03) : 409 - 412
  • [30] Long-term bone mineral density changes in antiretroviral-treated HIV-infected individuals
    Grant, Philip
    Kitch, Doug
    McComsey, Grace
    Collier, Ann
    Koletar, Sue
    Erlandson, Kristine
    Yin, Michael
    Bartali, Benedetta
    Ha, Belinda
    Melbourne, Kathy
    Brown, Todd
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2015, 18